Integrin receptor antagonists
US6784190B2 · kind B2 · utility
10Cited by
9References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2001 |
| Grant date | Aug 31, 2004 |
| Priority date | — |
| Expiry date | Feb 10, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.